background
coalit
epidem
prepared
innov
establish
develop
vaccin
contribut
prepared
outbreak
epidem
infecti
diseas
evid
vaccin
develop
cost
diseas
scarc
goal
estim
minimum
cost
achiev
vaccin
research
develop
prepared
target
portfolio
epidem
infecti
diseas
account
vaccin
pipelin
constraint
uncertainti
research
develop
prepared
outcom
assembl
pipelin
vaccin
candid
preclin
phase
prioriti
epidem
infecti
diseas
use
linear
regress
model
identifi
driver
develop
cost
preclin
end
phase
draw
publish
estim
vaccin
research
develop
probabl
success
simul
cost
advanc
vaccin
candid
end
phase
combin
find
determin
minimum
cost
progress
least
one
vaccin
end
phase
per
epidem
infecti
diseas
mean
stochast
optimis
model
end
phase
vari
us
million
million
million
rang
start
phase
million
million
billion
rang
start
preclin
cost
includ
cumul
cost
fail
vaccin
candid
research
develop
process
assum
candid
fund
made
avail
progress
least
one
vaccin
end
phase
epidem
infecti
diseas
would
cost
minimum
billion
billion
billion
rang
interpret
analysi
provid
new
evid
vaccin
research
develop
pipelin
associ
cost
epidem
infecti
diseas
highlight
fund
need
research
develop
gap
achiev
vaccin
research
develop
prepared
target
vaccin
power
tool
prevent
potenti
outbreak
epidem
infecti
diseas
becom
humanitarian
crise
develop
vaccin
requir
invest
howev
evid
would
cost
success
develop
sound
epidem
infecti
diseas
vaccin
portfolio
scarc
partli
pauciti
explicit
publicli
avail
cost
data
addit
littl
agreement
across
global
vaccin
develop
funder
epidem
infecti
diseas
invest
prioritis
stem
absenc
global
research
develop
portfolio
strategi
coordin
respons
ebola
epidem
west
africa
prioritis
pathogen
like
caus
sever
outbreak
near
futur
crimean
congo
haemorrhag
fever
chikungunya
ebola
lassa
marburg
middl
east
respiratori
syndrom
coronaviru
nipah
rift
valley
fever
sever
acut
respiratori
syn
drome
sever
fever
thrombocytopenia
syndrom
zika
updat
list
howev
diseas
remain
consider
epidem
prepared
import
gener
vaccin
develop
discoveri
licensur
cost
billion
dollar
take
year
complet
averag
chanc
failur
nation
health
secur
concern
exist
whether
due
natur
emerg
diseas
bio
terrorismrel
threat
govern
usa
uk
franc
germani
invest
research
develop
even
global
market
extrem
small
case
ebola
african
viral
haemorrhag
fever
shown
howev
worldwid
invest
epidem
infecti
diseas
small
new
entiti
coalit
epidem
prepared
innov
cepi
set
stimul
financ
coordin
develop
vaccin
epidem
infecti
diseas
especi
case
market
incent
alon
insuffici
owe
sporad
unpredict
emerg
epidem
infecti
diseas
largescal
vaccin
efficaci
studi
phase
almost
imposs
unless
ongo
epidem
infecti
diseas
epidem
part
cepi
scope
address
justincas
research
develop
prepared
gap
late
preclin
earli
clinic
safeti
efficaci
test
phase
epidem
infecti
diseas
vaccin
advanc
epidem
outbreak
cepi
commit
fundrais
invest
least
us
billion
previou
analysi
present
part
cepi
preliminari
busi
plan
examin
total
number
vaccin
candid
cepi
would
need
invest
today
advanc
two
three
candid
two
three
epidem
infecti
diseas
phase
stockpil
phase
emerg
use
year
billion
budget
constraint
studi
estim
cost
epidem
infecti
diseas
vaccin
develop
preclin
phase
end
phase
basi
new
data
analyt
tool
assum
one
phase
readi
vaccin
candid
reason
minimum
vaccin
research
develop
prepar
ness
target
per
epidem
infecti
diseas
studi
give
indic
number
minimum
vaccin
candid
cost
achiev
took
four
distinct
analyt
step
help
us
ascertain
cost
achiev
minimum
vaccin
research
develop
prepared
target
given
portfolio
epidem
infecti
diseas
first
map
exist
epidem
infecti
diseas
vaccin
research
develop
pipelin
collect
selfreport
cost
data
vaccin
develop
associ
epidem
infecti
diseas
vaccin
research
develop
preclin
phase
phase
second
evid
studi
almost
literatur
refer
vaccin
candid
develop
prioriti
epidem
infecti
diseas
appendix
inform
previous
neither
collat
systemat
actual
develop
statu
confirm
moreov
evid
cost
pharmaceut
research
develop
made
avail
sinc
least
howev
limit
mainli
chemic
drug
product
wherea
public
di
masi
colleagu
provid
foundat
numer
analys
critiqu
pharmaceut
research
develop
cost
sinc
conduct
evid
vaccinespecif
research
develop
cost
epidem
infecti
diseas
limit
hand
articl
publish
date
either
descript
base
expert
opinion
limit
data
input
valid
claim
focus
singl
pathogen
clinic
research
develop
phase
recent
studi
attempt
overcom
sever
limit
focus
analys
poverti
diseas
epidem
infecti
diseas
well
differenti
systemat
cost
associ
increment
versu
breakthrough
innov
studi
present
comprehens
dataset
vaccin
research
develop
candid
epidem
infecti
diseas
combin
systemat
search
substanti
size
literatur
confirm
current
develop
statu
candid
vaccin
develop
activ
field
moreov
studi
attempt
overcom
limit
identifi
previou
vaccin
research
develop
cost
analys
sever
way
first
consid
probabl
success
distribut
drawn
multipl
publish
estim
acknowledg
uncertainti
research
develop
explain
singl
sourc
second
draw
cost
data
histor
incur
project
cost
estim
infecti
diseas
vaccin
research
develop
report
vaccin
develop
activ
specif
field
epidem
infecti
diseas
give
us
confid
baselin
cost
estim
inform
model
provid
accur
reflect
total
invest
need
vaccin
develop
third
collect
data
suggest
cost
associ
new
technolog
may
differ
cost
associ
wellestablish
technologiesa
find
contradictori
prevail
assumpt
made
extant
literatur
analysi
suggest
indirect
cost
variat
cost
associ
differ
level
experi
organis
develop
product
drive
cost
estim
upward
direct
demonstr
possibl
combin
uptod
evid
vaccin
research
develop
pipelin
rigor
cost
analysi
method
gener
robust
estim
vaccin
research
develop
invest
need
epidem
infecti
diseas
method
find
benefit
futur
assess
global
health
research
develop
cost
improv
credibl
fund
need
claim
portfolio
plan
test
driver
vaccin
develop
cost
drawn
publish
studi
use
variou
statist
tech
niqu
third
drew
vaccin
research
develop
probabl
success
publish
estim
combin
selfreport
cost
data
simul
cost
adjust
probabl
success
advanc
vaccin
preclin
test
phase
within
mont
carlo
framework
fourth
use
cost
probabl
success
paramet
simul
determin
minimum
portfolio
cost
requir
achiev
least
one
phase
readi
candid
epidem
infecti
diseas
stochast
optimis
model
epidem
infecti
diseas
includ
studi
select
origin
blueprint
list
prioriti
emerg
infecti
diseas
list
recent
updat
exclud
chikungunya
sever
fever
thrombocytopenia
syndrom
includ
analysi
still
assum
consider
epidem
disrupt
potenti
drew
probabl
success
data
preclin
phase
literatur
tabl
remaind
data
collect
effort
focus
vaccin
candid
identi
ficat
associ
cost
wherea
vaccin
candid
identifi
twostep
approach
involv
literatur
review
survey
cost
data
collect
via
selfreport
survey
via
mine
cepi
databas
project
associ
budget
search
pubm
googl
googl
scholar
clinicaltrialsgov
intern
clinic
trial
registri
platform
countrylevel
trial
registri
nation
institut
health
report
pipelin
tracker
use
term
base
pathogen
name
vaccin
candid
name
develop
name
vaccin
combin
search
limit
last
year
jan
aug
ensur
complet
also
search
freeli
websit
press
releas
organis
identifi
epidem
infecti
diseas
vaccin
develop
ment
partner
scan
refer
list
relev
articl
miss
vaccin
candid
previou
search
acknowledg
pipelin
infor
mation
publicli
avail
updat
regularli
confirm
statu
vaccin
identifi
literatur
send
survey
organis
survey
ask
recipi
valid
current
statu
develop
prefil
list
vaccin
candid
team
collat
via
literatur
search
grant
databas
search
clinic
trial
registri
search
past
month
prior
survey
launch
includ
inform
diseas
phase
develop
ment
vaccin
technolog
type
product
develop
partner
clarifi
current
sourc
fund
develop
cost
incur
futur
fund
need
bring
vaccin
phase
potenti
phase
respons
potenti
diseas
outbreak
includ
stockpil
estim
phase
trial
emerg
use
latter
report
paper
specifi
main
driver
r
cost
technic
success
date
identifi
potenti
driver
futur
cost
technic
risk
bring
vaccin
candid
late
phase
clinic
develop
organis
identifi
owner
partner
support
epidem
infecti
diseas
vaccin
research
develop
appendix
survey
access
cepi
data
collect
new
confidenti
epidem
infecti
diseas
vaccin
research
develop
cost
data
total
compil
set
vaccin
research
develop
cost
entri
associ
nonclin
clinic
process
develop
manufactur
activ
appendix
check
consist
survey
data
cepi
data
vaccin
research
develop
ment
budget
prior
merg
singl
databas
appendix
dataset
exclud
cost
associ
basic
laboratori
research
activ
phase
efficaci
test
stockpil
investig
materi
phase
studi
literatur
suggest
research
develop
timelin
indirect
cost
sector
affili
ie
com
mercial
vs
noncommerci
public
privat
sector
licensur
track
record
vaccin
develop
licensur
track
record
vaccin
given
diseas
platform
technolog
complex
contribut
factor
vaccin
research
develop
cost
draw
evid
construct
sever
new
variabl
dichotom
perform
variou
correl
regress
analysi
varianc
anova
pairwis
test
order
ascertain
strongli
variabl
relat
whether
variabl
statist
signific
explanatori
factor
cost
explain
variat
observ
estim
cost
also
ran
hierarch
cluster
analysi
identifi
potenti
factor
captur
regress
model
comput
distanc
cluster
use
euclidean
metric
similar
measur
data
appendix
consid
three
key
input
paramet
estim
vaccin
research
develop
portfolio
cost
preclin
phase
vaccin
develop
ment
project
cost
research
develop
phase
probabl
success
research
develop
phase
number
vaccin
project
avail
pipelin
given
relev
vaccin
develop
licensur
track
record
larg
variat
selfreport
cost
explain
regress
cluster
analys
appendix
incorpor
uncertainti
mont
carlo
simul
specif
defin
cost
distribut
lower
upper
bound
divid
sampl
two
group
lower
bound
group
associ
cost
report
product
develop
vaccin
licensur
track
record
upper
bound
group
associ
cost
report
product
develop
previou
licensur
experi
group
construct
discret
cost
distribut
research
develop
phase
assign
equal
probabl
respect
self
report
cost
estim
addit
cost
construct
triangular
distri
bution
probabl
success
research
develop
phase
triangular
distribut
chosen
sinc
commonli
use
defin
rang
valu
uncertain
variabl
avail
data
either
scarc
heterogen
enough
clearli
dictat
appropri
rang
frequenc
possibl
valu
variabl
characteris
minimum
maximum
modal
like
valu
collect
defin
boundari
shape
distribut
triangl
appendix
move
singl
vaccin
candid
cost
portfolio
cost
account
probabl
success
ran
simul
time
time
randomli
draw
follow
cost
distributionsfor
group
research
develop
phase
iter
randomli
select
one
cost
estim
respect
distribut
probabl
success
distributionsfor
research
develop
phase
iter
randomli
drew
probabl
success
estim
respect
distribut
within
iter
sum
product
number
avail
vaccin
candid
probabl
success
cost
calcul
vaccin
candid
integ
advanc
end
phase
allow
estim
mean
ci
cost
adjust
probabl
success
iter
simul
analys
across
iter
allow
calcul
like
phase
outcom
associ
number
vaccin
candid
consid
appendix
wherea
simulationbas
analys
provid
analyt
depth
highlight
scenario
rel
low
capac
demonstr
optim
solut
minimis
maximis
object
epidem
infecti
diseas
vaccin
research
develop
given
inher
riski
natur
vaccin
research
develop
stochast
optimis
approach
like
repres
realist
reflect
uncertain
expect
pharmaceut
research
develop
process
sever
stochast
model
approach
propos
pharmaceut
research
develop
manag
address
variou
portfolio
optimis
stage
mani
vaccin
candid
would
ideal
need
enter
preclin
phase
phase
achiev
least
one
phase
outcom
eid
stage
much
invest
would
need
achiev
least
one
phase
outcom
eid
given
exist
new
preclin
vaccin
candid
made
avail
minimis
number
phase
readi
vaccin
candid
ci
minimis
us
cost
associ
develop
least
one
phase
readi
vaccin
candid
per
eid
ci
problem
see
literatur
overview
appendix
draw
previou
evid
built
twostag
stochast
optimis
modeli
stepwis
optimis
object
includ
uncertaintyto
identifi
optim
research
develop
portfolio
cost
progress
least
one
vaccin
candid
per
epidem
infecti
diseas
end
phase
stage
deriv
minimum
number
ideal
candid
requir
achiev
least
one
phase
readi
candid
epidem
infecti
diseas
start
preclin
test
phase
phase
respect
use
inform
evid
avail
pipelin
per
epidem
infecti
diseas
deriv
minimum
maximum
number
vaccin
candid
need
research
develop
phase
progress
least
one
end
phase
stage
drew
stage
find
defin
lower
upper
boundari
vaccin
candid
research
develop
phase
basi
estim
minimum
cost
success
develop
least
one
phase
readi
candid
per
epidem
infecti
diseas
provid
detail
overview
stochast
optimis
model
rational
formul
solut
search
method
appendix
summaris
object
decis
variabl
input
paramet
output
paramet
constraint
associ
solut
stage
optimis
problem
tabl
model
treat
cost
probabl
success
research
develop
phase
paramet
random
variabl
distribut
simul
stochast
model
approach
ensur
robust
optimis
findingsi
allow
us
run
probabilist
sensit
analys
output
model
captur
sourc
variabl
well
probabl
attach
differ
model
output
expect
see
appendix
detail
funder
role
studi
design
data
collect
data
analysi
interpret
write
studi
time
initi
design
project
chief
execut
fund
sourc
jar
princip
investig
grant
role
fund
followup
project
funder
side
take
current
fundingsourc
role
involv
studi
design
data
interpret
write
studi
dg
full
access
data
studi
final
respons
decis
submit
public
tabl
base
regress
analysi
previou
licensur
experi
indirect
cost
associ
ate
oper
model
vaccin
develop
statist
signific
explanatori
factor
drive
increas
research
develop
cost
previou
licensur
vaccin
given
diseas
potenti
drive
reduct
research
develop
cost
howev
licens
prophylact
vaccin
human
exist
epidem
infecti
diseas
hierarch
cluster
analysi
suggest
increas
research
develop
cost
clinic
research
develop
phase
may
also
potenti
associ
increas
industri
sector
affili
substanti
variat
report
cost
explain
despit
consid
sever
factor
includ
addit
research
develop
ment
timelin
previou
licen
sure
trackrecord
platform
technolog
appendix
simul
suggest
advanc
singl
epidem
infecti
diseas
vaccin
candid
pre
clinic
end
phase
cost
million
million
rang
assum
risk
failur
tabl
howev
total
cost
progress
one
epidem
infecti
diseas
vaccin
success
end
phase
depend
probabl
success
shape
vaccin
research
develop
pipelin
figur
demonstr
account
probabl
success
assum
clinic
vaccin
candid
exist
given
epidem
infecti
diseas
preclin
candid
would
requir
least
one
progress
end
phase
cost
million
million
billion
rang
similarli
six
ten
phase
candid
would
tabl
high
probabl
success
high
cost
scenario
cost
phase
readi
candid
rang
would
amount
billion
billion
rang
seven
epidem
infecti
diseaseszika
ebola
chikungunya
rift
valley
fever
marburg
lassahav
suffici
vaccin
pipelin
invest
made
avail
guarante
success
phase
outcom
regardless
probabl
success
realiti
phase
readi
candid
alreadi
exist
ebola
low
probabl
success
scenario
success
progress
vaccin
end
phase
guarante
nipah
given
avail
candid
epidem
infecti
diseas
vaccin
pipelin
crimean
congo
haemorrhag
fever
sever
acut
respiratori
syndrom
sever
fever
thrombo
cytopenia
syndrom
compris
candid
phase
outcom
predict
invest
even
optimist
probabl
success
base
stochast
optimis
tabl
lower
invest
would
need
smaller
number
vaccin
candid
achiev
phase
outcom
chikungunya
zika
rift
valley
fever
middl
east
respiratori
syndrom
marburg
clinic
vaccin
pipelin
modestli
matur
higher
invest
ment
across
larger
number
preclin
vaccin
candid
would
need
lassa
phase
readi
vaccin
guarante
new
preclin
candid
would
need
ad
vaccin
pipelin
nipah
crimean
congo
haemorrhag
fever
sever
acut
respiratori
syndrom
sever
fever
thrombocytopenia
syndrom
collect
phase
readi
candid
guarante
epidem
infecti
diseas
probabilist
sensit
analysi
embed
find
stochast
model
appendix
analysi
demonstr
wherea
zero
phase
outcom
unlik
given
number
vaccin
candid
support
research
develop
phase
low
high
probabl
success
scenario
outcom
previous
mention
beyond
one
phase
readi
candid
per
epidem
infecti
diseas
depend
probabl
success
scenario
low
cost
associ
high
probabl
success
distribut
number
vaccin
candid
would
need
support
per
high
probabl
success
high
cost
scenario
achiev
minimum
phase
outcom
per
epidem
infecti
diseas
overal
portfolio
cost
would
reduc
us
billion
billion
rang
contrast
scenario
high
cost
associ
low
probabl
success
distribut
number
vaccin
candid
would
need
fund
per
low
probabl
success
low
cost
scenario
success
advanc
least
one
vaccin
end
phase
success
case
howev
associ
portfolio
cost
would
increas
billion
billion
rang
appendix
vaccin
research
develop
cost
estim
produc
studi
highlight
need
substanti
invest
prioriti
epidem
infecti
diseas
minimum
vaccin
research
develop
prepar
ness
targetsi
least
one
phase
readi
vaccin
candid
per
epidem
infecti
diseasear
achiev
given
rel
larg
number
preclin
candid
low
probabl
success
associ
analysi
identifi
sever
diseas
area
upstream
vaccin
research
develop
pipelin
today
insuffici
highlight
need
entri
new
vaccin
candid
preclin
develop
chanc
minimum
vaccin
research
develop
prepared
target
increas
moreov
demonstr
higher
vaccin
research
develop
cost
particular
clinic
research
develop
cost
like
associ
greater
industri
sector
affili
previou
licensur
experi
vaccin
develop
experi
assum
translat
higher
probabl
success
invest
project
could
progress
epidem
infecti
diseas
vaccin
end
phase
analysi
demonstr
possibl
use
simulationoptimis
techniqu
gener
vaccin
develop
cost
estim
combin
pipelin
cost
inform
subject
multipl
object
rang
constraint
studi
mean
fulli
combin
uptod
evid
research
develop
pipelin
project
cost
rigor
analyt
method
demonstr
invest
need
altern
scenario
moreov
done
studi
consider
research
develop
cost
driver
uncertainti
cost
probabl
success
inform
analysi
evid
cost
pharmaceut
research
develop
made
avail
sinc
least
howev
limit
mainli
chemic
drug
product
wherea
di
masi
colleagu
public
provid
foundat
numer
analys
critiqu
pharmaceut
research
develop
cost
sinc
conduct
evid
vaccinespecif
research
develop
cost
epidem
infecti
diseas
scarc
sever
reason
first
process
vaccin
develop
might
differ
substanti
drug
develop
implic
scale
intens
resourc
use
associ
cost
research
develop
phase
second
complex
platform
technolog
use
develop
vaccin
might
influenc
research
develop
cost
literatur
assum
new
technolog
licensur
trackrecord
induc
higher
research
develop
cost
wellestablish
technolog
third
complex
pathogen
vaccin
develop
might
affect
research
develop
cost
vaccin
pathogen
licens
vaccin
alreadi
exist
assum
cost
less
hand
articl
publish
vaccin
research
develop
cost
date
either
descript
base
expert
opinion
littl
data
input
valid
claim
focus
singl
pathogen
clinic
research
develop
phase
studi
one
draw
sourc
data
assumpt
otherhav
attempt
overcom
sever
limit
focus
analys
either
poverti
diseas
epidem
infecti
diseas
characteris
poor
commerci
potenti
well
differenti
systemat
cost
associ
increment
versu
breakthrough
innov
studi
attempt
overcom
limit
identifi
previou
vaccin
research
develop
cost
analys
tri
deviat
recent
studi
focus
epidem
infecti
diseas
vaccin
research
develop
sever
way
first
although
draw
probabl
success
estim
publish
evid
specif
vaccin
research
develop
consid
probabl
success
distribut
instead
point
estim
acknowledg
uncertainti
research
develop
attribut
specif
explanatori
factor
regress
analys
shown
second
draw
cost
data
histor
incur
project
cost
estim
infecti
diseas
vaccin
research
develop
report
vaccin
develop
activ
specif
field
epidem
infecti
diseas
give
us
confid
baselin
cost
estim
inform
model
provid
accur
reflect
total
invest
need
epidem
infecti
diseas
vaccin
develop
third
collect
data
suggest
cost
associ
new
technolog
differ
substanti
cost
associ
wellestablish
technologiesa
find
contradictori
prevail
assumpt
made
literatur
date
may
compound
complex
certain
pathogen
make
difficult
disassoci
pathogen
specif
technologyspecif
cost
driver
unless
one
access
granular
cost
data
howev
plausibl
explan
perhap
cost
variat
strongli
associ
busi
model
rather
technolog
variou
vaccin
develop
epidem
infecti
diseas
oper
industri
nonindustri
sector
statist
analysi
suggest
platform
technolog
substanti
explanatori
factor
averag
vaccin
develop
project
cost
even
control
assumpt
data
may
nest
respect
individu
pathogen
instead
indirect
cost
variat
cost
associ
differ
level
experi
organis
develop
product
drive
cost
estim
upward
studi
sever
limit
first
averag
vaccin
develop
project
cost
estim
simulationoptimis
approach
draw
base
selfreport
data
vaccin
develop
despit
statist
analys
consist
check
cepi
literatur
sourc
minimis
bia
bia
like
persist
selfreport
cost
project
impli
certain
price
innov
vaccin
develop
will
accept
order
engag
research
develop
may
differ
across
sector
organis
oper
differ
busi
model
intern
cost
structur
howev
practic
project
cost
area
rel
low
commerci
potenti
like
establish
payerdevelop
negoti
around
risk
benefit
share
balanc
payer
constraint
develop
appetit
financi
risk
exposur
coupl
unexpect
circumst
unforeseen
regulatori
requir
technolog
spillov
research
develop
activ
factor
may
well
drive
realis
vaccin
research
develop
ment
expenditur
either
way
downward
upward
compar
estim
provid
studi
second
assumpt
higher
probabl
success
associ
experienc
vaccin
develop
vice
versa
base
common
sens
insight
share
vaccin
develop
survey
process
howev
clear
evid
literatur
exist
indisput
substanti
claim
implic
epidem
infecti
diseas
vaccin
research
develop
cost
estim
could
consider
one
hand
higher
probabl
success
associ
less
experienc
vaccin
develop
could
well
mean
portfolio
cost
achiev
least
one
phase
outcom
per
prioriti
epidem
infecti
diseas
would
lower
analysi
suggest
hand
lower
probabl
success
manifest
experienc
vaccin
develop
effort
would
suggest
much
higher
portfolio
cost
report
studi
third
number
vaccin
candid
associ
portfolio
cost
report
studi
guarante
full
certainti
one
phase
outcom
per
epidem
infecti
diseas
would
achiev
probabl
success
cost
scenario
given
confid
interv
appli
small
chanc
suggest
vaccin
candid
cost
would
fail
meet
clinic
develop
target
increas
confid
interv
analysi
would
improv
certainti
phase
outcom
howev
given
varianc
report
cost
probabl
success
estim
lower
upper
limit
vaccin
candid
requir
associ
portfolio
cost
would
increas
substanti
model
fourth
analysi
limit
scope
prioriti
epidem
infecti
diseas
mani
infecti
diseas
epidem
potenti
deserv
attent
accord
differ
prioriti
list
expert
perspect
estim
cost
draw
contem
poran
inform
made
avail
vaccin
research
develop
pipelin
epidem
infecti
diseas
provid
overal
price
tag
bring
vaccin
epidem
infecti
diseas
success
phase
pipelin
data
collect
work
would
need
increas
number
diseas
includ
cost
analysi
fifth
studi
report
estim
fund
flow
epidem
infecti
diseas
vaccin
research
develop
survey
least
neglect
diseas
area
recent
ebola
differ
vaccin
develop
probabl
differ
capac
access
intern
extern
financ
suggest
fund
gap
support
epidem
infecti
diseas
vaccin
research
develop
may
overal
smaller
cost
estim
report
studi
well
vari
sector
type
organis
research
develop
epidem
infecti
diseas
vaccin
may
also
suggest
practic
transit
probabl
success
develop
phase
also
like
vari
organis
technic
reason
also
access
financ
bottleneck
would
plausibl
assumpt
make
organis
previou
licensur
experi
market
vaccin
also
better
access
financ
therefor
financi
reason
like
face
higher
probabl
success
vaccin
research
develop
programm
captur
high
probabl
success
high
cost
scenario
sixth
hierarch
cluster
analysi
highlight
possibl
margin
differ
cost
industri
versu
nonindustri
actor
differ
size
data
sampl
suffici
larg
confid
label
observ
smaller
versu
larger
industri
actor
composit
partnership
develop
vaccin
clearcut
sector
subsector
geograph
region
variabl
addit
definit
challeng
constitut
smaller
larger
industri
actor
suggest
research
would
need
understand
report
greater
certainti
signific
differ
cost
associ
size
sector
affili
geograph
locat
vaccin
develop
seventh
studi
estim
cost
small
part
much
bigger
pictur
epidem
infecti
diseas
vaccin
research
develop
prepared
research
develop
scope
analysi
restrict
preclin
phase
phase
exclud
cost
associ
phase
trial
stockpil
phase
readi
materi
regulatori
deliveri
activ
includ
incountri
infrastructur
support
emerg
respons
activ
critic
element
vaccin
research
develop
prepar
ness
need
respons
public
health
emerg
issu
pertain
clinic
trial
design
locat
target
popul
clinic
studi
mani
factor
like
drive
clinic
develop
cost
explicitli
consid
studi
issu
togeth
factor
pertain
stockpil
strategi
phase
trial
complex
differ
diseas
outbreak
scenario
clinic
trial
design
regulatori
requir
deserv
special
attent
separ
analysi
hope
futur
studi
provid
eighth
simulationoptimis
framework
assum
one
phase
readi
vaccin
candid
expect
per
diseas
suffici
research
develop
prepared
target
efficaci
test
respons
epidem
assumpt
might
case
histor
probabl
success
phase
literatur
consid
howev
uniqu
clinic
trial
design
speedi
launch
might
requir
mitig
wane
diseas
outbreak
might
requir
differ
threshold
clinic
regulatori
success
public
health
emerg
moreov
experi
ebola
recent
epidem
infecti
diseas
outbreak
shown
interest
funder
support
vaccin
research
develop
respons
outbreak
wither
togeth
wane
epi
demic
addit
phase
readi
vaccin
candid
would
requir
addit
multimillion
invest
ment
case
also
substanti
new
invest
phase
test
emerg
respons
whether
one
phase
vaccin
candid
support
particular
epidem
infecti
diseas
therefor
also
issu
consider
funder
decis
maker
epidem
infecti
diseas
vaccin
research
develop
space
vaccin
epidem
infecti
diseas
need
world
attent
invest
effort
respond
effect
potenti
futur
epidem
avert
humanitarian
crise
studi
offer
com
prehens
set
epidem
infecti
diseas
vaccin
research
develop
pipelin
cost
find
reproduc
methodolog
identifi
optim
research
develop
portfolio
associ
invest
need
across
sever
diseas
broadli
demonstr
better
understand
diseas
specif
product
research
develop
pipelin
associ
cost
rigor
analys
benefit
assess
invest
need
global
health
research
develop
improv
credibl
claim
around
fund
requir
portfolio
plan
contributor
dg
led
model
design
data
collect
analysi
interpret
articl
write
ttl
kh
cole
vaccin
pipelin
cost
data
collect
contribut
analysi
interpret
articl
find
ak
cole
statist
analysi
supervis
overal
method
design
data
analysi
interpret
find
td
nch
contribut
vaccin
pipelin
data
collect
analysi
interpret
find
jmr
pmh
contribut
method
valid
analysi
interpret
find
jar
supervis
overal
method
design
contribut
data
analysi
interpret
find
declar
compet
interest
